Cretostimogene Grenadenorepvec
Pre-clinicalActive 0 watching 0 views this week๐ค Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Muscle Invasive Bladder Cancer
Conditions
Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer, Bladder Cancer
Trial Timeline
โ โ โ
NCT ID
NCT06443944About Cretostimogene Grenadenorepvec
Cretostimogene Grenadenorepvec is a pre-clinical stage product being developed by CG Oncology for Non-Muscle Invasive Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06443944. Target conditions include Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06443944 | Pre-clinical | Active |
| NCT06567743 | Phase 2 | Recruiting |
| NCT06111235 | Phase 3 | Active |
| NCT04452591 | Phase 3 | Active |
Competing Products
18 competing products in Non-Muscle Invasive Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG) | AstraZeneca | Phase 3 | 77 |
| Durvalumab + BCG | AstraZeneca | Phase 3 | 77 |
| Durvalumab + Monalizumab | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + BCG | Merck | Phase 3 | 77 |
| Pembrolizumab | Merck | Phase 1/2 | 41 |
| Sacituzumab tirumotecan + Rescue medication + Supportive care measures | Merck | Phase 1/2 | 41 |
| Eciskafusp Alfa + BCG Medac Strain | Roche | Phase 1 | 33 |
| PF-06801591 + Bacillus Calmette-Guerin | Pfizer | Phase 3 | 76 |
| PF-08052667 + Sasanlimab + BCG + PF-02921367 | Pfizer | Phase 1 | 32 |
| BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 ฮผg/instillation). ) + BCG( 50mg/Instillation) | ImmunityBio | Phase 1/2 | 38 |
| N-803 and BCG + N-803 and Gemcitabine | ImmunityBio | Phase 2 | 49 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| UGN-301 + UGN-201 + Gemcitabine | UroGen Pharma | Phase 1 | 28 |
| AU-011 | Aura Biosciences | Phase 1 | 25 |
| TARA-002 | Protara Therapeutics | Phase 1 | 25 |
| TARA-002 | Protara Therapeutics | Phase 2 | 44 |
| TARA-002 | Protara Therapeutics | Phase 1 | 25 |
| PD-L1/IDO Peptide Vaccine + Pembrolizumab | IO Biotech | Phase 1 | 25 |